Deramiocel: DMD upper-limb FDA decision
Capricor reconfirmed a November 22, 2026 FDA target in its October HOPE-3 extension update. A major amendment moved the review from August 22. The proposed indication focuses on upper limb function in Duchenne muscular dystrophy; the actual label scope matters.
What matters
Follow the exact application, indication and requested label. An FDA decision concerns the drug program, while the company’s stock also reflects its other assets and business.
- August 22, 2026 is a superseded target.
- Advisory-committee discussion and positive trial data are not regulatory approval. Define acceptable label scope rather than treating every DMD authorization as equivalent.
Primary evidence
FDA target 2026-11-22 — not a guaranteed decision date
Potential outcome market
Will FDA approve deramiocel for the submitted DMD application focused on upper limb function by a separately fixed evidence cutoff?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.